The trial will enroll 3,000 healthy participants in the United States and will assess the safety and effectiveness of two doses of the company’s vaccine candidate, mRNA-1273, given 28 days apart.
Moderna has submitted applications seeking emergency use authorization in the United States and EU after full results from a late-stage study showed the vaccine was 94.1% effective in adults with no serious safety concerns. Rival Pfizer/BioNTech have also sought EUA after their coronavirus vaccine’s two-dose regimen proved 95% effective against COVID-19 and had no major safety issues.
Meanwhile, a panel of outside advisers to the U.S. Food and Drug Administration will meet on Thursday to discuss whether to recommend the use of Pfizer’s vaccine for people aged 16 and older.Moderna’s adolescents study is being conducted in collaboration with the Biomedical Advanced Research and Development Authority, a part of the U.S. Department of Health and Human Services.
“Our goal is to generate data in the spring of 2021 that will support the use of mRNA-1273 in adolescents in advance of the 2021 school year,” Chief Executive Officer Stephane Bancel said in a statement.
Now ...?
🙏🏻🙏🏻
Human guinea pigs, our children, how lucky!
95% only bad news(
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.